Investment Thesis
Penumbra demonstrates solid fundamental growth with 17.5% revenue expansion and exceptional financial health characterized by zero debt and $241.3M cash. Strong free cash flow generation (19.6% FCF margin) and high gross margins (67.6%) indicate a well-managed medical device business, though low ROE (2.2%) and ROA (1.7%) suggest capital efficiency challenges requiring attention.
Strengths
- Strong revenue growth of 17.5% YoY with robust 67.6% gross margin in stable medical device sector
- Exceptional balance sheet strength: zero long-term debt, $241.3M cash, 6.02x current ratio
- Excellent free cash flow generation at $73.3M (19.6% FCF margin) with healthy $87M operating cash flow
Risks
- Low return on equity (2.2%) and return on assets (1.7%) indicate inefficient capital deployment despite profitability
- Operating margin at 10.2% is modest for medical device sector, suggesting potential pricing or cost structure pressures
- Unusual EPS spike of +1155.6% YoY may indicate prior-period distortions affecting earnings quality assessment
Key Metrics to Watch
- Operating margin expansion and capital efficiency metrics (ROE/ROA improvement)
- Revenue growth sustainability and free cash flow conversion maintenance
- Insider Form 4 filing patterns and capital allocation decisions
Financial Metrics
Revenue
374.8M
Net Income
32.6M
EPS (Diluted)
$0.82
Free Cash Flow
73.3M
Total Assets
1.9B
Cash
241.3M
Profitability Ratios
Gross Margin
67.6%
Operating Margin
10.2%
Net Margin
8.7%
ROE
2.2%
ROA
1.7%
FCF Margin
19.6%
Balance Sheet & Liquidity
Current Ratio
6.02x
Quick Ratio
3.95x
Debt/Equity
0.00x
Debt/Assets
22.4%
Interest Coverage
51.25x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T06:23:15.463204 |
Data as of: 2026-03-31 |
Powered by Claude AI